6533b856fe1ef96bd12b31e1

RESEARCH PRODUCT

Cooperative studies of chemoprophylaxis after transurethral resection of bladder tumors

G.b. IngargiolaMichele Pavone-macalusoMaria Tripi

subject

OncologyCancer Researchmedicine.medical_specialtymedicine.medical_treatmentAntineoplastic AgentsToxicologylaw.inventionRandomized controlled triallawInternal medicinemedicineCarcinomaHumansCombined Modality TherapyPharmacology (medical)DoxorubicinTeniposidePharmacologyCisplatinClinical Trials as TopicChemotherapyMulti-Institutional Systemsbusiness.industryPyridoxinePrognosismedicine.diseaseCombined Modality TherapyCarcinoma PapillaryClinical trialUrinary Bladder NeoplasmsOncologyDoxorubicinChemoprophylaxisCisplatinNeoplasm Recurrence LocalbusinessThiotepamedicine.drug

description

Large cooperative trials are more likely than series studied by small groups to bring about significant progress in the field of intravesical adjuvant chemotherapy of superficial bladder tumor. Multicenter randomized trials involving large numbers of patients have been conducted in Europe by the EORTC Urological Group. The Group's main objectives were to compare the efficacy of thio-TEPA, VM-26, epodyl, Adriamycin, and cisplatin, against no treatment, and to study the prophylactic effect of oral pyridoxine and evaluate the main prognostic factors. The results obtained so far are reported. Preliminary information is also given about the Blinst study, a multicenter open investigation of local chemotherapy with doxorubicin (Adriamycin), with special reference to evaluation of the importance of different modalities of treatment with a single drug.

yearjournalcountryeditionlanguage
1983-11-01Cancer Chemotherapy and Pharmacology
https://doi.org/10.1007/bf00256711